The Immune Checkpoint Inhibitors Market is segmented by Inhibitor Type (CTLA-4 Inhibitors, PD-1 Inhibitors, Others), Application (Hodgkin Lymphoma, Kidney Cancers, Melanoma, Non-small Cell Lung Cancer, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region (North America, Europe, Asia-Pacific, and the Rest of the World). This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global market. The historic years considered for the study are 2016-2019, the base year is 2020, and the forecast period is 2021-2026.
The rise in prevalence of cancer across the globe and growing awareness of immune checkpoint inhibitors propel the product demand. Also, technological developments in screening procedures for cancer, increase in government initiatives to cure cancer, growing healthcare expenditures, and rise in public awareness further boost the market growth. However, the high cost associated with research activities is likely to restrain the industry growth.
The market has been classified into CTLA-4 inhibitors, PD-1 inhibitors, and others. The PD-1 inhibitors segment accounted for a substantial market share in 2020. This is mainly ascribed to the increased volume of research activities, approvals, and surge in prescriptions of these drugs such as nivolumab and pembrolizumab. In addition, the growing adoption of pembrolizumab, the first PD-1 inhibitor since its approval, owing to its proven efficiency to treat multiple FDA-Approved indications like melanoma, further boosts the segment growth.
The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly attributed to the strong presence of well-developed healthcare infrastructure and favorable government initiatives. Moreover, rising innovations in technologically advanced products, immense per capita health expenditures; and increasing prevalence of various chronic diseases such as skin cancer, diabetes, urothelial carcinomas, and lung cancers, which further proliferate the regional growth.
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to firstname.lastname@example.org.